Long-term virological outcome in chronic hepatitis B patients with a partial virological response to entecavir |
Jo, Yu Jung
(Department of Internal Medicine, Inje University Ilsan Paik Hospital)
Kim, Kyung-Ah (Department of Internal Medicine, Inje University Ilsan Paik Hospital) Lee, June Sung (Department of Internal Medicine, Inje University Ilsan Paik Hospital) Kim, Nam-Hoon (Department of Internal Medicine, Inje University Ilsan Paik Hospital) Bae, Won Ki (Department of Internal Medicine, Inje University Ilsan Paik Hospital) Song, Tae June (Department of Internal Medicine, Inje University Ilsan Paik Hospital) Kim, Jeong Wook (Department of Internal Medicine, Inje University Ilsan Paik Hospital) |
1 | Guo XF, Zhang CX, Liu Y, Wu F, Luo X. Drug-resistant genes at hepatitis B virus polymerase region during entecavir treatment. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 2013;35:444-446. |
2 | Papatheodoridis G, Goulis J, Manolakopoulos S, et al. Changes of HBsAg and interferon-inducible protein 10 serum levels in naive HBeAg-negative chronic hepatitis B patients under 4-year entecavir therapy. J Hepatol 2014;60:62-68. DOI ScienceOn |
3 | Chang TT, Gish RG, de Man R, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006;354:1001-1010. DOI ScienceOn |
4 | Lai CL, Shouval D, Lok AS, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006;354:1011-1020. DOI ScienceOn |
5 | Chang TT, Lai CL, Kew Yoon S, et al. Entecavir treatment for up to 5 years in patients with hepatitis B e antigenpositive chronic hepatitis B. Hepatology 2010;51:422-430. DOI ScienceOn |
6 | Chang TT, Liaw YF, Wu SS, et al. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology 2010;52:886-893. DOI ScienceOn |
7 | Hosaka T, Suzuki F, Kobayashi M, et al. Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hepatology 2013;58:98-107. |
8 | Papatheodoridis GV, Dimou E, Dimakopoulos K, et al. Outcome of hepatitis B e antigen-negative chronic hepatitis B on long-term nucleos(t)ide analog therapy starting with lamivudine. Hepatology 2005;42:121-129. |
9 | Zoulim F, Perrillo R. Hepatitis B: reflections on the current approach to antiviral therapy. J Hepatol 2008;48 Suppl 1:S2-S19. DOI ScienceOn |
10 | Lai CL, Gane E, Liaw YF, et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 2007;357:2576-2588. DOI ScienceOn |
11 | Korean Association for the Study of the Liver. KASL Clinical Practice Guidelines: management of chronic hepatitis B. Clin Mol Hepatol 2012;18:109-162. DOI |
12 | Yang SC, Lee CM, Hu TH, et al. Virological response to entecavir reduces the risk of liver disease progression in nucleos(t)ide analogue-experienced HBV-infected patients with prior resistant mutants. J Antimicrob Chemother 2013;68:2154-2163. DOI ScienceOn |
13 | Wang CC, Tseng TC, Wang PC, Lin HH, Kao JH. Baseline hepatitis B surface antigen quantitation can predict virologic response in entecavir-treated chronic hepatitis B patients. J Formos Med Assoc 2014;113:786-793. DOI ScienceOn |
14 | Zoutendijk R, Reijnders JG, Brown A, et al. Entecavir treatment for chronic hepatitis B: adaptation is not needed for the majority of naive patients with a partial virological response. Hepatology 2011;54:443-451. DOI ScienceOn |
15 | Bang SJ, Kim BG, Shin JW, et al. Clinical course of patients with insufficient viral suppression during entecavir therapy in genotype C chronic hepatitis B. Dig Liver Dis 2013;45:600-605. DOI ScienceOn |
16 | Liaw YF, Chu CM. Hepatitis B virus infection. Lancet 2009;373:582-592. DOI ScienceOn |
17 | Ko SY, Choe WH, Kwon SY, et al. Long-term impact of entecavir monotherapy in chronic hepatitis B patients with a partial virologic response to entecavir therapy. Scand J Gastroenterol 2012;47:1362-1367. DOI ScienceOn |
18 | Schiff ER, Lee SS, Chao YC, et al. Long-term treatment with entecavir induces reversal of advanced fibrosis or cirrhosis in patients with chronic hepatitis B. Clin Gastroenterol Hepatol 2011;9:274-276. DOI ScienceOn |
![]() |